SNAP25变异I67N:人体神经元中的突触表型,药物反应和蛋白质组变化
Maiken Østergaard1, Paola Barbagallo1, Henriette Reventlow S Frederiksen2
1Department of Neuroscience, University of Copenhagen, 2200 Copenhagen N, Denmark.
Brain : a journal of neurology
|April 4, 2025
概括
脑神经病变是一种严重的神经发育障碍. 这项研究使用人类干细胞来模拟SNAP25变体,揭示突触缺陷和4-氨基胺的潜在治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 干细胞生物学 干细胞生物学
背景情况:
- 突触神经病变是一种严重的遗传神经发育障碍,影响突触功能.
- 目前这些疾病的治疗方法仅限于症状管理.
- 对于人类实验模型来开发有针对性的疗法是非常需要的.
研究的目的:
- 创建和表征人类诱导多能干细胞 (hiPSC) 衍生神经元,具有特定的SNAP25致病变体 (I67N).
- 调查与这种变体相关的突触表型和分子变化.
- 探索SNARE病变的潜在治疗干预措施.
主要方法:
- 产生了CRISPR/Cas9工程的hiPSC线路与SNAP25 I67N变种.
- 利用NGN2驱动的分化转化为前脑的谷氨酸性神经元.
- 进行了电生理学,免疫染色和蛋白质学,以分析突触功能和蛋白质表达.
主要成果:
- 该SNAP25 I67N变种损害了突触传输,减少了唤起和自发释放,并改变了短期可塑性.
- 与另一种变体 (V48F) 相比,观察到明显的突触表型.
- 4-阿米诺皮里丁药物改善了与I67N变异相关的突触缺陷.
- 蛋白质组分析发现了下调的突触蛋白,包括CALB1和SCN2A.
结论:
- 基于hiPSC的模型对于研究神经发育障碍及其潜在的突触机制是有效的.
- 该研究发现了由SNAP25 I67N变异引起的特定突触传输缺陷.
- 针对像4-氨基二这样的药物来治疗突触功能障碍,在SNARE病变中显示出个性化治疗策略的前景.
关键词:
它们是SNARE蛋白质.触觉神经元 (Autaptic Neurons) 是一种神经元.发育性和性脑病变.遗传性是一种遗传性.诱导多能干细胞的诱导干细胞.突触蛋白质组学 突触蛋白质组学 突触蛋白质组学更多相关视频
10:08Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
Published on: July 20, 2022
2.1K
09:21Author Spotlight: Generating Neuronal Phenotypic Profiles - A Protocol to Culture and Image Human Midbrain Dopaminergic Neurons
Published on: July 7, 2023
1.4K
相关概念视频
01:29Excitatory and Inhibitory Effects of Neurotransmitters
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...